ATE518884T1 - Spezifisch an chemokin beta-4 bindende antikörper - Google Patents
Spezifisch an chemokin beta-4 bindende antikörperInfo
- Publication number
- ATE518884T1 ATE518884T1 AT03721955T AT03721955T ATE518884T1 AT E518884 T1 ATE518884 T1 AT E518884T1 AT 03721955 T AT03721955 T AT 03721955T AT 03721955 T AT03721955 T AT 03721955T AT E518884 T1 ATE518884 T1 AT E518884T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- immune system
- well
- system diseases
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37656102P | 2002-05-01 | 2002-05-01 | |
PCT/US2003/013414 WO2003092597A2 (en) | 2002-05-01 | 2003-04-30 | Antibodies that specifically bind to chemokine beta-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE518884T1 true ATE518884T1 (de) | 2011-08-15 |
Family
ID=29401362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03721955T ATE518884T1 (de) | 2002-05-01 | 2003-04-30 | Spezifisch an chemokin beta-4 bindende antikörper |
Country Status (6)
Country | Link |
---|---|
US (3) | US7375192B2 (de) |
EP (1) | EP1534752B1 (de) |
AT (1) | ATE518884T1 (de) |
AU (1) | AU2003225237A1 (de) |
CA (1) | CA2484121A1 (de) |
WO (1) | WO2003092597A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539235A2 (de) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Spezifisch an reg iv bindende antikörper |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
US20060263357A1 (en) * | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
TWI417301B (zh) * | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
WO2008021263A2 (en) * | 2006-08-11 | 2008-02-21 | Medarex, Inc. | Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
JP5211790B2 (ja) * | 2007-03-26 | 2013-06-12 | 住友化学株式会社 | Dnaメチル化測定方法 |
WO2009026117A2 (en) * | 2007-08-16 | 2009-02-26 | Glaxo Group Limited | Novel compounds |
JP2012197228A (ja) * | 2009-07-27 | 2012-10-18 | Kyoto Univ | 肝炎の治療剤もしくは予防剤 |
NZ611269A (en) | 2010-11-19 | 2015-03-27 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
US8715572B2 (en) | 2011-05-19 | 2014-05-06 | Abbott Laboratories | Method and apparatus for detection, analysis, and collection of rare cellular events |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897348A (en) | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
CH681625A5 (de) | 1988-12-08 | 1993-04-30 | Sandoz Ag | |
US5212073A (en) | 1989-05-12 | 1993-05-18 | Genetics Institute, Inc. | Process for producing human JE cytokine |
US5179078A (en) | 1989-05-12 | 1993-01-12 | Dana Farber Cancer Institute | Method of suppressing tumor formation in vivo |
DE69020573T3 (de) | 1989-09-25 | 1999-12-16 | Crc Technology Ltd., London | Verfahren zur wachstumshemmung von stammzellen. |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
JPH06503710A (ja) | 1990-09-14 | 1994-04-28 | カイロン コーポレイション | 酵母細胞におけるマクロファージ誘導タンパク質(mip)の発現 |
US6001649A (en) | 1990-11-29 | 1999-12-14 | Societe Anonyme: Elf Sanofi | Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production |
US5401651A (en) | 1991-10-16 | 1995-03-28 | Walz; Alfred | DNA encoding ENA-78, a neutrophil activating factor |
US5306709A (en) | 1991-11-15 | 1994-04-26 | The University Of Pennsylvania | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins |
US5413778A (en) | 1992-10-05 | 1995-05-09 | The Regents Of The University Of Michigan | Labelled monocyte chemoattractant protein material and medical uses thereof |
US5346686A (en) | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
US5474983A (en) | 1993-03-15 | 1995-12-12 | The Research Foundation Of State University Of New York | Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
JPH0789866A (ja) | 1993-09-21 | 1995-04-04 | Nippon Kayaku Co Ltd | 感染防御剤 |
JP3677288B2 (ja) | 1993-12-22 | 2005-07-27 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | マクロファージ炎症蛋白質−3、−4および−1▲下γ▼ |
JPH10500301A (ja) | 1994-05-16 | 1998-01-13 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | マクロファージ遊走阻止因子−3 |
DE69428460T2 (de) | 1994-05-16 | 2002-05-23 | Human Genome Sciences, Inc. | Chemotaktisches protein |
ES2235172T3 (es) | 1994-08-23 | 2005-07-01 | Human Genome Sciences, Inc. | Quimioquina humana beta-9. |
WO1996005856A1 (en) | 1994-08-23 | 1996-02-29 | Human Genome Sciences, Inc. | Human chemokine polypeptides |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
WO1996009062A1 (en) | 1994-09-23 | 1996-03-28 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
US5602008A (en) | 1994-11-29 | 1997-02-11 | Incyte Pharmaceuticals, Inc. | DNA encoding a liver expressed chemokine |
AU723891B2 (en) | 1995-06-05 | 2000-09-07 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
WO1996039520A1 (en) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-12 |
WO1996039521A1 (en) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-13 |
ZA968896B (en) | 1995-10-24 | 1997-04-24 | Smithkline Beecham Corp | Method of mobilizing hematopoietic stem cells |
WO1997015594A1 (en) | 1995-10-24 | 1997-05-01 | Smithkline Beecham Corporation | Novel chemokine for mobilizing stem cells |
EP0885293B1 (de) | 1996-02-23 | 2006-06-07 | Human Genome Sciences, Inc. | Menschliche chemokin-polypeptide. |
JP2000508527A (ja) | 1996-03-27 | 2000-07-11 | アイコス コーポレイション | 単球走化性タンパク質―5物質及び方法 |
EP0909321A2 (de) | 1996-07-05 | 1999-04-21 | Schering Corporation | Chemokin reagenzien aus saeugetieren |
GB9617923D0 (en) | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
AU4243097A (en) | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
WO1998014573A1 (en) | 1996-09-30 | 1998-04-09 | The General Hospital Corporation | Mcp-4 and mcp-5: novel chemokines |
WO1998017800A1 (fr) | 1996-10-17 | 1998-04-30 | Shionogi & Co., Ltd. | Larc, nouvelle chimiokine cc humaine |
CA2242384A1 (en) | 1996-11-15 | 1998-05-22 | Indiana University Foundation | Exodus chemokine materials and methods |
WO1999047674A2 (en) | 1998-03-18 | 1999-09-23 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
EP1149113A1 (de) * | 1999-02-03 | 2001-10-31 | Schering Corporation | Verwendung von agonisten oder antagonisten von mip-3a in der therapie |
-
2003
- 2003-04-30 US US10/513,705 patent/US7375192B2/en not_active Expired - Fee Related
- 2003-04-30 AT AT03721955T patent/ATE518884T1/de not_active IP Right Cessation
- 2003-04-30 CA CA002484121A patent/CA2484121A1/en not_active Abandoned
- 2003-04-30 EP EP03721955A patent/EP1534752B1/de not_active Expired - Lifetime
- 2003-04-30 AU AU2003225237A patent/AU2003225237A1/en not_active Abandoned
- 2003-04-30 WO PCT/US2003/013414 patent/WO2003092597A2/en not_active Application Discontinuation
-
2008
- 2008-05-19 US US12/123,419 patent/US7943741B2/en not_active Expired - Fee Related
-
2011
- 2011-01-31 US US13/017,658 patent/US20110223178A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1534752A4 (de) | 2006-08-09 |
EP1534752A2 (de) | 2005-06-01 |
US7943741B2 (en) | 2011-05-17 |
EP1534752B1 (de) | 2011-08-03 |
US7375192B2 (en) | 2008-05-20 |
WO2003092597A2 (en) | 2003-11-13 |
AU2003225237A1 (en) | 2003-11-17 |
US20080233134A1 (en) | 2008-09-25 |
CA2484121A1 (en) | 2003-11-13 |
WO2003092597A3 (en) | 2005-03-31 |
AU2003225237A8 (en) | 2003-11-17 |
US20110223178A1 (en) | 2011-09-15 |
US20060275210A1 (en) | 2006-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010747A (es) | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. | |
WO2003054216A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
WO2003089575A3 (en) | Antibodies that specifically bind to tl5 | |
DK0910647T3 (da) | Human DNase i hyperaktive varianter | |
ATE518884T1 (de) | Spezifisch an chemokin beta-4 bindende antikörper | |
WO2004000997A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2004013287A3 (en) | Antibodies against c3a receptor | |
EA201201067A1 (ru) | Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела, или его связывающего фрагмента, или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), полинуклеотид, вектор и клетка-хозяина, их включающая композиция | |
DE3856180D1 (de) | Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren | |
WO2003102136A3 (en) | Antibodies that specifically bind to neurokinin b | |
WO2004003144A3 (en) | Antibodies that specifically bind to reg iv | |
WO2003080856A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2003085093A3 (en) | Antibodies that specifically bind to gmad | |
WO2005016236A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2004016753A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003086301A3 (en) | Antibodies that specifically bind to tr2 | |
WO2003078572A3 (en) | Therapeutic polypeptides, nucleic acids encoding same and methods of use | |
WO2003042367A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003022998A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2002079377A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003040329A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2003085124A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
ES2188653T3 (es) | Variantes de la dnasa i humana. | |
WO2003085096A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |